Terlipressin bests placebo in type 1 hepatorenal syndrome
EU to vaccinate ‘all who need’ by end of summer: official
4 March 2021Two hundred nine US counties face a crisis in staffing ICUs that care for COVID-19 patients
4 March 2021Terlipressin bests placebo in type 1 hepatorenal syndrome
(HealthDay)—For patients with type 1 hepatorenal syndrome (HRS-1), terlipressin is more effective than placebo for reversal of HRS, according to a study published in the March 4 issue of the New England Journal of Medicine.
